| Literature DB >> 27556033 |
Michal Slany1, Vit Ulmann2, Iva Slana1.
Abstract
The nontuberculous mycobacteria are typically environmental organisms residing in soil and water. These microorganisms can cause a wide range of clinical diseases; pulmonary disease is most frequent, followed by lymphadenitis in children, skin and soft tissue disease, and rare extra pulmonary or disseminated infections. Mycobacterium avium complex is the second most common cause of pulmonary mycobacterioses after M. tuberculosis. This review covers the clinical and laboratory diagnosis of infection caused by the members of this complex and particularities for the treatment of different disease types and patient populations.Entities:
Mesh:
Year: 2016 PMID: 27556033 PMCID: PMC4983314 DOI: 10.1155/2016/4387461
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
M. tuberculosis and M. avium complex taxonomy.
| Member | Etiology |
|---|---|
|
| |
|
| Human tuberculosis, occasionally in animals in close contact with infected patients |
|
| Tuberculosis in bovines and other animals; humans are mainly infected by drinking raw milk |
|
| The vaccine strain |
|
| Tuberculosis in bovines and other animals; humans are infected through the same pathways as for |
|
| Tuberculosis in rodents, rarely other animals and humans |
|
| Human infection, not detected in animals |
|
| Human tuberculosis, rarely in animals |
|
| Tuberculosis in pinnipeds; animals bred in captivity are the main source of infection for caregivers |
|
| |
|
| |
|
| Avian tuberculosis, mycobacterioses in pigs and humans |
|
| Pig tuberculosis, human mycobacterioses |
|
| Human infections |
|
| Human infections |
|
| Human and animal infections |
|
| Human infection |
|
| Human infection |
|
| Human infection |
|
| Human infection |
|
| ? |
?: yet to be confirmed.
Antibiotic regimes, summarization.
| Combination | Duration | Comments | |
|---|---|---|---|
| Pulmonary | |||
| Cavitary disease | Clarithromycin 500–1000 mg/d or | Up to 12 months, negative culture | In case of macrolide resistance or intolerance clofazimine and quinolones may be useful based on strain resistance profiles |
| Bronchiectatic-fibronodular | Clarithromycin 1000 mg/d or | Intermittent three times weekly | Adjuvant therapy of underlying disease, bronchodilators, airways clearance support, smoking cessation, and nutrition |
| Hypersensitivity | Prednisone 1-2 mg/kg/daily | 4–8 weeks, repeated exposure must be avoided | Long postexposure observation to exclude lung disease progression |
|
| |||
| Extrapulmonary | |||
| Systemic, disseminated, and HIV infection | Clarithromycin 500 mg/twice daily or | Up to 12 months | Prevention |
| Skin, soft tissue, and osteoarticular disease | Chirurgical debridement, excision | In case of indolent persistence, supportive in more excessive involvement: | |
| Lymphadenitis |
| Duration and dosage not established,see pulmonary, consider Ethambutol with caution in infants! | Antibiotic treatment only in cases where extirpation is contraindicated or with poor outcome after surgery, considering superinfection with other microorganisms |
The most frequent sequencing targets used for identification of nontuberculous mycobacteria.
| Target gene | Name | Primer type | Sequence 5′ → 3′ | Length of the product (bp) | Reference |
|---|---|---|---|---|---|
|
| 16S27f | Forward | AGAGTTTGATCMTGGCTCAG | 921 | Harmsen et al., 2003 [ |
|
| |||||
|
| Tb11 | Forward | ACCAACGATGGTGTGTCCAT | 441 | Telenti et al., 1993 [ |
|
| |||||
| ITS | 16S-1511f | Forward | AAGTCGTAACAAGGTARCCG | Approx. 380 | Harmsen et al., 2003 [ |
|
| |||||
|
| Myco-F | Forward | GGCAAGGTCACCCCGAAGGG | 764 | Adékambi et al., 2003 [ |
Amplicon size is not uniform due to the 16S-23S spacer length variability.
(a) Pulmonary localization
| Signs | Laboratory findings | Signs | ||
|---|---|---|---|---|
| Bronchiectasis | ++ | Repeated massive isolation | +++ | Cavitary, HIV |
| Nonspecific, CF, and COPD† | +/− | Repeated isolation | +++ | Systemic |
| − | Single isolation | + | ||
| Low benefit of antibiotic treatment versus adverse effects | Antibiotic treatment necessary | |||
| Colonization: COPD, CF, coniosis-mild course, mycobacterial overgrowth-exacerbation; infection: chronic course, CT (RTG) progressive changes, and systemic signs. | ||||
(b) Extrapulmonary localization
| Signs | Laboratory findings | Signs | ||
|---|---|---|---|---|
| Skin, soft tissue | +++ | Repeated massive isolation | +++ | HIV, systemic organs |
| Lymphadenitis | ++ | Repeated isolation | ++ | Osteoarticular, tenosynovial |
| +/− | Single isolation | + | ||
| AT therapy necessary | ||||
+++Strong recommendation for treatment.
++Recommendation for treatment.
+Weak recommendation for treatment (repeated sample collection necessary), managing intermittent treatment.
−No treatment.
Based on isolated MAC species. From invasively taken sample (biopsy, bronchoscopy).
†Consider contamination, repeated exposition to environmental source, and household screening.